MedTrace Logo

An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.

NCT04330872 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-04-02

No results posted yet for this study

Summary

Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.

Conditions

  • Stroke, Ischemic

Interventions

DRUG

Enteric Coated Aspirin Tablet

Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).

DRUG

Plain Aspirin

Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).

Sponsors & Collaborators

  • Hamad Medical Corporation

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2020-01-04
Completion
2020-03-04

Countries

  • Qatar

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04330872 on ClinicalTrials.gov